ArticleFrontiers in pharmacology2026
Impact of valproate co-medication and age on lurasidone exposure: a population pharmacokinetic study and real-world evaluation in Chinese psychiatric inpatients.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To characterize the population pharmacokinetics (PPK) of lurasidone in Chinese psychiatric inpatients and to quantify the sources of inter-individual variability, with a specific focus on the impact of valproate (VPA) co-medication and age on drug exposure. Methods: Routine therapeutic drug monitoring (TDM) data were collected from 156 patients (providing 212 serum concentrations). A PPK model was developed utilizing a nonlinear mixed-effects modeling approach (NONMEM). Model performance was assessed via goodness-of-fit plots, normalized prediction distribution errors (NPDE), and bootstrap analysis. Additionally, model-based simulations were performed to estimate concentration profiles stratified by age and VPA co-medication. Results: A one-compartment model with first-order absorption and elimination best described the data. The typical estimate for apparent clearance (CL/F) was 339 L·h Conclusion: The pharmacokinetics of lurasidone in Chinese inpatients were effectively characterized by the established PPK model. Lurasidone exposure in this population is generally lower than the AGNP reference range, particularly in patients receiving VPA. Age and VPA co-medication are critical determinants of CL/F. These findings suggest that TDM interpretation should be adjusted for these factors, and optimal concentration targets for Chinese patients may need to be revisited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.